Dr. Mikkael Sekeres is Professor of Medicine with Tenure and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, FL. He earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine, Philadelphia. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston, MA. He is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndromes (MDS) International Foundation, chairs the American Society of Hematology (ASH) Treatment Guidelines for Older Adults with Acute Myeloid Leukemia (AML), is a Councilor on the ASH Executive Committee and a Fellow of the American Society of Clinical Oncology, and formerly chaired the Oncologic Drugs Advisory Committee of the FDA.

Dr. Sekeres’ research focuses on patients with MDS and older adults with AML, and he has been the national and international primary study investigator on dozens of phase 1/2/3 trials. He is the author or coauthor of over 500 peer-reviewed manuscripts and 650 abstracts, with an H-index of 100. He was the inaugural editor-in-chief of the ASH Clinical News magazine; he is on the editorial board of several journals and is Associate Editor for the Journal of Clinical Oncology and a Section Editor for UpToDate; has written over 100 essays for the New York Times, the Wall Street Journal, the Washington Post, Huffington Post, Slate, and The Hill, among others; and has authored 8 books, including When Blood Breaks Down: Life Lessons from Leukemia (The MIT Press, 2020); Drugs and the FDA: Safety, Efficacy, and the Public’s Trust (The MIT Press, 2022); and a book tentatively titled Chasing Truth in Cancer (University of Toronto Press, 2026).